NEW YORK (Reuters) - Merck & Co Inc's fast growing diabetes drug Januvia proved effective in helping patients lower blood sugar in combination with Takeda's Actos, and when used along with insulin ...
NEW YORK (Reuters) - Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company ...
Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results